Mabion signs agreement for rights to sell Mabion CD20 drug in EU and Balkans
Thursday, November 10, 2016
Mabion SA Said that it signed a long-term cooperation agreement with Mylan N.V's wholly-owned unit, Mylan Ireland, for exclusive rights to sell Mabion CD20- oncology drug biosimilar to MabThera/Rituximab in all countries of the European Union and the Balkan countries.
Mylan will also support the company in the process of registration Mabion CD20 drug by the European Medicines Agency.
The company will receive from Mylan the advance payment in the amount of $10 million and additional payments for the implementation of the key steps of the deal in the total amount of up to $35 million, depending on the submission and approval of admission to market the product in key countries and royalties based on annual net sales.
Source : reuters.com
